The GIP / GLP-1 / glucagon triple agonist: mechanism, trial data and how it compares.
12 articles
Weight Loss & GLP-1
GLP-1 receptor agonist research is evolving rapidly beyond injectable semaglutide: oral formulations, triple agonists (GLP-1/GIP/glucagon), CNS-targeted analogs, and organ-protective applications. Research guide to the next-generation GLP-1 pipeline and the mechanistic frontiers being explored in 2025–2026.
6 min read
Peptides & Recovery
GLP-1 receptor agonists improve insulin resistance through multiple mechanisms beyond GLP-1R signaling — including hepatic gluconeogenesis suppression, adipose tissue remodeling, and GIP receptor co-stimulation. Advanced research guide to GLP-1 insulin sensitization pathways and experimental models.
5 min read
Weight Loss & GLP-1
Semaglutide, retatrutide, and tirzepatide represent three generations of incretin-based therapy with distinct receptor targets. Research comparison of mechanisms, clinical trial weight loss data, receptor pharmacology, and research applications for each compound class.
4 min read
Weight Loss & GLP-1
GLP-1 receptor agonists are among the most studied compounds in metabolic biology research. Protocol design guide covering GLP-1/GIP/GCG receptor mechanisms, compound selection for obesity and glucose homeostasis research, and in vitro and in vivo endpoint design.
4 min read
Weight Loss & GLP-1
How to source research-grade retatrutide in Europe. What to look for in a verified supplier — HPLC certificates, EU warehouse stock, ZPHC-quality vials and pens. Updated 2025.
7 min read
Weight Loss & GLP-1
Complete guide to retatrutide research dosing protocols — Phase 2 escalation schedules, reconstitution calculations for vials, and pen format instructions. Based on published clinical trial data.
7 min read
Weight Loss & GLP-1
Head-to-head comparison of retatrutide (triple GIP/GLP-1/glucagon agonist) vs tirzepatide (dual GIP/GLP-1). Phase 2 and Phase 3 data, mechanism differences, and what the research says about each.
9 min read
Weight Loss & GLP-1
A mechanistically rational weight loss research stack combining semaglutide, retatrutide, HGH Fragment 176-191, and MOTS-c — covering appetite suppression, thermogenesis, lipolysis, and metabolic enhancement in one protocol.
7 min read
Weight Loss & GLP-1
A mechanistic deep-dive into triple GIP/GLP-1/glucagon receptor co-agonism — why each receptor contributes distinct weight loss and metabolic effects, and why their combination is synergistic rather than merely additive.
8 min read
Weight Loss & GLP-1
Deep analysis of the NEJM Phase 2 retatrutide trial (Jastreboff 2023) — 24% weight loss at 48 weeks, dose-response data, glycemic outcomes, and what the results mean for obesity pharmacotherapy research.
7 min read
Peptides & Recovery
Head-to-head research comparison of retatrutide (triple agonist) vs semaglutide (GLP-1 agonist) — mechanism differences, weight loss magnitude, glycemic control, side effect profiles, and research protocol selection.
7 min read
Peptides & Recovery
Retatrutide (LY3437943) is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — producing 24–26% body weight loss in Phase 2 trials. Research overview of structure, mechanism, and clinical data.
8 min read
Hilma Biocare
Triple GIP/GLP-1/Glucagon agonist. Next-generation metabolic research compound.
98.5%· Janoshik
ZPHC
Retatrutide 10mg (5×2mg) lyophilized by ZPHC. Triple GIP/GLP-1/Glucagon agonist.
99%+· ZPHC
ZPHC
Retatrutide 15mg single vial by ZPHC. Starter dose for triple agonist research.
99%+· ZPHC
ZPHC
Retatrutide 20mg kit (5×4mg) by ZPHC. GIP/GLP-1/Glucagon triple agonist.
99%+· ZPHC
For laboratory research only. Not for human consumption.
Resellers, laboratories and publishers: apply for partner pricing, volume terms and a dedicated representative.
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Products sold by JuicedPharma are not medicines. By ordering you confirm you are a qualified person buying for research in compliance with applicable regulations. Full disclaimer